本帖最后由 老马 于 2012-1-13 21:20 编辑 ; K+ z" @8 d' ^; {6 U
& \- @' @0 `9 i4 Q' o7 b8 v爱必妥和阿瓦斯丁的比较
; H6 X' T/ W% Q! J( f8 F
) U7 l0 N* R) G8 J4 z, ohttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
% J* I' g% g' p! _
( X: }' `6 w0 P1 F( V
# q1 ^1 [: \/ a9 o7 U5 b
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
1 E1 h h' G" q) C. E==================================================, j/ b& a4 C D/ B/ @/ c. L8 ?
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL): N+ \9 b1 o! Z& { x! c, Q4 f
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
* m% H% @1 X2 T4 ~3 O9 M" L1 zResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.4 C; |2 r, q& Y! N H. N, h; R
|